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Anti-ﬁbrotic and organ protective effects of brain natriuretic peptide (BNP) have been reported. In
this study, effects of BNP on liver ﬁbrosis were examined in the carbon tetrachloride (CCl4)-induced
liver ﬁbrosis model using BNP-transgenic (Tg) and wild-type (WT) mice. Twice-a-week intraperito-
neal injections of CCl4 for 8 weeks resulted in massive liver ﬁbrosis, augmented transforming
growth factor (TGF)-b1 and type I procollagen a1 chain (Col1a1) mRNA expression, and the hepatic
stellate cell (HSC) activation in WTmice, all of which were signiﬁcantly suppressed in Tg mice. These
observations indicate that BNP inhibits liver ﬁbrosis by attenuating the activation of HSCs.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Natriuretic peptides (NPs) are a family of peptides, which con-
sist of atrial, brain, and C-type NPs (ANP, BNP, and CNP, respec-
tively) [1]. NPs’ biological actions are mainly mediated by two NP
receptors: guanylyl cyclase (GC)-A and GC-B [1]. NPs increase
intracellular cGMP concentrations upon ligand binding. ANP and
BNP are cardiac hormones produced mainly in the cardiac atria
and ventricles, respectively, and play important roles to maintain
cardiovascular homeostasis by activating GC-A [1]. CNP binds to
GC-B, and the CNP/GC-B system takes part in the endochondral
ossiﬁcation and the vascular remodeling [1].
Carbon tetrachloride (CCl4)-induced liver ﬁbrosis is one of the
most utilized animal models for liver ﬁbrosis. CCl4 selectively dam-
age hepatocytes around central veins (centrilobular regions),
which highly express cytochrome P450 2E1 (CYP2E1) that change
CCl4 into reactive oxygen species (ROS) [2]. Damaged hepatocytes
recruit leukocytes and stimulate Kupffer cells to secrete several
proinﬂammatory cytokines such as tumor necrosis factor-a, whichchemical Societies. Published by E
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amura).activate hepatic stellate cells (HSCs). Transforming growth factor
(TGF)-b1 released from damaged hepatocytes also activates adja-
cent HSCs [3]. Activated HSCs become myoﬁbroblast-like cells,
which express a-smooth muscle actin (SMA), intensely proliferate,
profoundly synthesize collagen, and produce proﬁbrotic cytokines
including TGF-b1, leading to the development of liver ﬁbrosis [3].
Also in non-alcoholic steatohepatitis (NASH) and alcoholic steato-
hepatitis, CYP2E1-derived ROS induce hepatocellular damage and
HSC activation, leading to liver ﬁbrosis [2,4].
While antiﬁbrotic effects of CNP were shown in lungs and
hearts of experimental animal models [5,6], we showed antiﬁbrotic
effects of BNP in the heart and kidneys [7,8]. In this study, we used
BNP-transgenic (Tg) mice [9] in the CCl4-induced liver ﬁbrosis
model to investigate effects of BNP on liver damage and ﬁbrosis.2. Materials and methods
2.1. Animals
Male wild-type (WT) C57BL/6 J mice (Shimizu Experimental
Supplies, Kyoto, Japan) and male BNP-Tg mice of line 75 over-
expressing BNP (8 weeks of age, 25–30 g of body weight) were
used. The BNP-Tg mice harbor a transgene that expresses BNP
under the control of the human serum amyloid P promoter, which
is active in the liver after birth, and their plasma BNP concentra-
tions were comparable to those in patients with severe congestivelsevier B.V. All rights reserved.
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their livers were about 10-fold higher than their plasma BNP con-
centrations, but the majority of BNP-like immunoreactivities in
their livers were proBNP, which is less active than mature peptide
[9]. Mice were housed in a speciﬁed pathogen free facility with a
12-h light/dark cycle. Access to food and water was ad libitum
throughout the study period. Mice were intraperitoneally injected
with CCl4 of 1 ml/kg body weight twice a week for 2–8 weeks to in-
duce liver ﬁbrosis. Mice were killed with the intraperitoneal injec-
tion of pentobarbital 3 days after the ﬁnal CCl4 injection, and livers
were either ﬁxed with 4% phosphate-buffered paraformaldehyde
and embedded in parafﬁn for histological examination or immedi-
ately frozen in liquid nitrogen for the extraction of RNA. The exper-
imental protocol of this study is approved by the Animal Research
Committee, Kyoto University.
2.2. Histological analyses
Tissue sections were stained with hematoxylin and eosin or Sir-
ius red to evaluate histological changes and collagen ﬁber deposi-
tion, respectively. To quantify the extent of ﬁbrosis, percentages of
Sirius red-positive pixels were measured in ﬁve randomly selected
microscope ﬁelds at 40 magniﬁcation and averaged for each
specimen by a technician, who did not know the genotype of eachFig. 1. Typical images of Hematoxylin and Eosin (HE) and Sirius red staining of
livers from wild-type (WT) and BNP-transgenic (Tg) mice before CCl4 injections (A),
and after 2 (B), 4 (C), and 8 weeks of twice-a-week CCl4 injections (D) are shown.
Scale bars indicate 100 lm. Collagen ﬁbrils are stained red by Sirius red. (E) The
extent of liver ﬁbrosis is quantiﬁed as the percentage of Sirius red-positive areas
(before CCl4 injections, n = 5 for each genotype; after 2, 4, and 8 weeks of CCl4
injections, n = 4, 4, and 8 for each genotype, respectively). Data of WT and Tg mice
are shown with open and closed columns, respectively. *P < 0.05 vs. WT mice at
each time point; #P < 0.05 vs. before CCl4 injections in the same genotype by
ANOVA.specimen. The sections were also subjected to immunohistochem-
istry with an antibody against mouse a-SMA (M0851, DAKO, Den-
mark), as described previously [10].
2.3. Extraction and analysis of RNA
Total RNA extracted from livers using an RNeasy Mini kit (Qia-
gen, Tokyo, Japan) was reverse-transcribed using a PrimeScript RT-
PCR kit (Takara Bio, Otsu, Japan), and subjected to a real-time
quantitative PCR using an ABI Prism 7300 Sequence Detection Sys-
tem (Applied Biosystems, Foster City, CA) with SYBR Premix Ex Taq
(Takara Bio, Otsu, Japan) to evaluate mRNA levels of TGF-b1, type I
procollagen a1 chain (Col1a1), and a-SMA, according to the man-
ufacturers’ instructions. Levels of mRNA were normalized with
those of a house keeping gene, b-actin. The primers used are shown
in Supplementary Table 1.
2.4. Statistics
All values are expressed as means ± standard errors of the
mean. Statistical differences in averages between two groups and
among three or more groups were assessed by unpaired t-test
and ANOVA, respectively.
3. Results and discussion
Before CCl4 injections and after 2 weeks of repeated CCl4 injec-
tions, hepatocellular damage and liver ﬁbrosis were not evident
both in WT and Tg mice (Fig. 1A and B). In WT mice, hepatocellular
necrosis with inﬂammatory cell inﬁltration and ﬁbrosis appeared
in centrilobular regions after 4 weeks of CCl4 injections (Fig. 1C),
and hepatocellular necrosis was observed throughout the liver
and septal ﬁbrosis emerging from centrilobular regions formed
central–central bridging necrosis after 8 weeks of CCl4 injections
(Fig. 1D). This is the typical time course of histological changes in
this model [3], showing the model was adequately prepared in this
study. In Tg mice, the extent of liver ﬁbrosis was signiﬁcantly sup-
pressed compared with that of WTmice after 8 weeks of CCl4 injec-
tions (Fig. 1D and E).
Hepatic TGF-b1 and Col1a1 mRNA levels were not different be-
tweenWT and Tg mice before CCl4 injections (Fig. 2). After 2 weeks
of CCl4 injections, hepatic TGF-b1 and Col1a1 mRNA levels tended
to increase compared with those before CCl4 injections in WT mice,Fig. 2. Real-time quantitative PCR analysis of hepatic transforming growth factor
(TGF)-b1 (A) and type I procollagen a1 chain (Col1a1) (B) mRNA levels in wild-type
(WT, open columns) and BNP-transgenic (Tg, closed columns) mice before CCl4
injections (n = 5 for each genotype) and after 2, 4, and 8 weeks of CCl4 injections
(n = 4, 4, and 8 for each genotype, respectively). The average of mRNA levels of each
gene in WT livers before CCl4 injections is set 1.0 arbitrary unit (a.u.).
*P < 0.05 vs.
WT mice at each time point; #P < 0.05 vs. before CCl4 injections in the same
genotype by ANOVA.
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mice (Fig. 2). After 4 or 8 weeks of CCl4 injections, hepatic TGF-b1
and Col1a1 mRNA levels signiﬁcantly increased compared with
those before CCl4 injections in WT mice (Fig. 2). Only TGF-b1 mRNA
levels were suppressed in Tg mice compared with those in WT
mice after 4 weeks of CCl4 injections, and both TGF-b1 and Col1a1
mRNA levels were suppressed in Tg mice compared with those in
WT mice after 8 weeks of CCl4 injections (Fig. 2). We reported that
BNP suppresses TGF-b1 and Col1a1 mRNA levels and exerts anti-ﬁ-
brotic and organ protective effects in the heart and kidneys [7,8].
This study added the liver to targets of those effects of BNP.
Alpha-SMA-positive cells, which are activated, myoﬁbroblastic
HSCs, were not detected in livers of WT and Tg mice before CCl4
injections (Fig. 3A). After 8 weeks of CCl4 injections, lots of a-
SMA-positive cells were observed in regions of bridging necrosis
in WT mice, but they were hardly seen in Tg mice (Fig. 1D and
3A). Hepatic a-SMA mRNA levels were attenuated in Tg mice com-
pared with WT mice after 8 weeks of CCl4 injections (Fig. 3B).
An in vitro study showed that activated human HSCs expressed
GC-B without GC-A, suggesting that CNP has a potential to prevent
HSCs’ activation via GC-B and to counteract liver ﬁbrosis [11]. On
the contrary, it was reported that both quiescent and activated hu-
man HSCs expressed GC-A mRNA [13]. It was also reported that
HSCs isolated from rats with CCl4-induced cirrhosis expressed a
higher number of ANP receptors compared with HSCs isolated
from normal rats, indicating that in vivo activation of HSCs is asso-
ciated with an up-regulation of ANP receptors [12]. GC-A mRNA
expression was detected also in hepatocytes and Kupffer cells iso-
lated from rat livers, and ANP could prevent ischemia-reperfusion
injury of rat livers, which was caused by ROS generated by Kupffer
cells, via GC-A [13]. During the course of our experiments, Ishigaki
and colleagues reported that a continuously intravenous infusion
of ANP could suppress dimethylnitrosamine (DMN)-induced liver
damage and ﬁbrosis by inhibiting HSC activation in rats [14]. It is
speculated that an activation of GC-A can prevent liver ﬁbrosis
due to hepatocellular damage, because either an intravenous
administration of ANP in rats or increased circulating BNP concen-
trations in Tg mice could prevent hepatocellular damage and liver
ﬁbrosis in different experimental models.
In the heart, signaling through GC-A inhibits angiotensin II type
I receptor-mediated cardiac hypertrophy and ﬁbrosis [15]. Olme-
sartan, an angiotensin II receptor blocker, reportedly inhibited liver
ﬁbrosis caused by NASH in mice [16]. An activation of GC-A might
inhibit the renin–angiotensin system to protect the liver, but fur-
ther studies will be needed to clarify the precise molecular
mechanisms.Fig. 3. Hapatic stellate cell activation in carbon tetrachloride-induced liver ﬁbrosis.
(A) Immunohistochemical detections of a-smooth muscle actin (SMA) in livers of
wild-type (WT) and BNP-transgenic (Tg) mice before and after 8 weeks of CCl4
injections. Scale bars indicate 100 lm. (B) Real-time quantitative PCR analysis of
hepatic a-SMA mRNA levels in WT and Tg mice after 8 weeks of CCl4 injections
(n = 8 for each genotype). The average of mRNA levels in WT livers is set 1.0
arbitrary unit (a.u.). *P < 0.05 vs. WT mice by unpaired t-test.In conclusion, BNP could inhibit the CCl4-induced liver ﬁbrosis
through the prevention of hepatocellular damage and HSC activa-
tion. Our ﬁndings may open up the possibility that BNP is thera-
peutically applicable for the prevention of liver ﬁbrosis.
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